Hikma stood out among its industry peers when it recently reported results for the first half of 2020 that were “ahead of initial expectations.” Recently ranked by Generics Bulletin as the world’s 15th largest off-patent company by sales (Also see "Major Players Swap Positions Among Industry Top 50" - Generics Bulletin, 20 August, 2020.), the firm’s first-half operating profit rose by 25% to $297m on sales up by 8% to $1.132bn, at a time when much of the off-patent industry was experiencing adverse effects from the COVID-19 pandemic, balancing out short-term increases in demand that had been enjoyed earlier in the year. (Also see "Hikma’s First-Half Profits Leap By A Quarter" - Generics Bulletin, 11 August, 2020.)
Speaking exclusively to Generics Bulletin, CEO Siggi Olafsson has set out his belief that Hikma’s firm grasp of fluctuating demand...
